NCT02536976View on ClinicalTrials.gov

Mirabegron in Parkinson Disease and Impaired Cognition

PHASE4CompletedINTERVENTIONAL
Enrollment

7

Participants

Timeline

Start Date

December 31, 2015

Primary Completion Date

August 1, 2018

Study Completion Date

August 1, 2018

Conditions
Parkinson DiseaseOveractive BladderImpaired Cognition
Interventions
DRUG

mirabegron

DRUG

Placebo

Trial Locations (1)

55427

Struthers Parkinson's Center, Golden Valley

All Listed Sponsors
lead

HealthPartners Institute

OTHER

NCT02536976 - Mirabegron in Parkinson Disease and Impaired Cognition | Biotech Hunter | Biotech Hunter